BGT Shares Bio-Gene Technology Limited
ASX · ASXLast in our picks 2026-10-19 — not in the current list; analysis below is from that screen
R&D incentive receipt and pesticide-technology commercialization provide speculative near-term re-rating potential.
Future value: $0.03 (+78.57%) · 6-12 months
Signal breakdown
- ▸Share price momentum after R&D tax incentive receipt.
- ▾Below 50-day MA (-19.26%)
- ▾Near 52-week low (5.4% of range)
- ▸~79% upside to price target
Is BGT a buy right now?
Trend: BGT is trading below the 50-day average (-15.00%), RSI 45 — neutral momentum, with a 3-month return of -5.56%.
Valuation & quality: Bio-Gene Technology Limited trades on price-to-book 3.40; fundamentals show net margin -216.0%, return on equity -125.4%, revenue growth 105.7% year on year.
Our screen: ACCUMULATE (score 1) — R&D incentive receipt and pesticide-technology commercialization provide speculative near-term re-rating potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +33.30% | -25.00% | -33.30% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Bio-Gene Technology Limited
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.